Ventfort is a tissue-derived preparation of small peptides isolated from young calf aortic tissue within the Khavinson bioregulator program. It is a peptide mixture rather than a single defined sequence. The entry reviews vascular and microcirculation research, including age-related vessel changes, while distinguishing its supplement context from a conventional pharmaceutical.
What Is Ventfort?
Ventfort is a vascular-specific peptide bioregulator containing a complex of low-molecular-weight peptides (≤10,000 Da) isolated from the aortic tissue of young calves (≤12 months). Developed within the Khavinson Cytomax system at the St. Petersburg Institute of Bioregulation and Gerontology, it is studied for its ability to normalize metabolism and structure in blood-vessel wall cells, improve microcirculation, regulate blood lipids, and support arterial and venous health — with reported benefits in atherosclerosis, microcirculation disorders, senile purpura, and age-related vascular fragility. It is marketed as a biologically active food additive (dietary supplement) rather than a conventional pharmaceutical. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Research Background
Ventfort belongs to the Khavinson Cytomax class of organ-derived peptide bioregulators — short peptide complexes extracted from specific tissues to restore tissue-specific gene expression patterns and cellular function. The A-3 peptide complex is isolated from bovine aortic tissue using a proprietary extraction and purification process. Experimental work at the St. Petersburg Institute demonstrated tissue-specific action on vascular wall cells, improving trophism and metabolism. Clinical studies in patients with arterial atherosclerosis and senile purpura confirmed favorable impact on vascular health, microcirculation, and blood lipid profiles — supporting its use as a medical-preventive adjunct and longevity vascular tool.
Mechanism of Action
Ventfort's proposed mechanisms center on tissue-specific epigenetic modulation. As a natural peptide complex (not a single synthetic peptide), it is thought to interact with vascular wall cell DNA to restore normal gene expression patterns — normalizing connexin expression, endothelial metabolism, stress resistance, and angiogenic pathways. A documented secondary mechanism is lipid regulation: clinical data show reduction in blood cholesterol and atherogenic lipoprotein levels in atherosclerosis subjects. Effects build gradually over a 10–30-day course and persist for months via structural vascular remodeling rather than sustained plasma levels — the peptide itself clears rapidly, but its downstream gene-expression and structural changes are durable.
Quick Reference
Member reference tables summarize the compound's research parameters.
IAS clinical study in patients with arterial atherosclerosis demonstrated improved general health, better vascular wall condition (normalization of functional and morphological changes), and regulated blood cholesterol and lipoprotein levels — reducing atherogenic lipoproteins and decreasing risk of vascular defects.
Lipid Regulation
Ventfort reduces blood cholesterol and atherogenic lipoprotein levels in atherosclerosis subjects, contributing to decreased plaque formation risk. Modern commentaries extend this to conceptual anti-plaque and vascular-damage-repair roles via selective gene regulation in vascular wall cells.
Microcirculation & Senile Purpura
Moderate Evidence
Senile Purpura (Age-Related Vascular Fragility)
In elderly patients with senile purpura (subcutaneous bleeding from fragile capillaries), Ventfort courses of 10–30 days improved vascular wall function, microcirculation, and reduced purpura manifestations. Recommended for elderly maintenance of vascular system function.
Microcirculation Disorders
Ventfort is studied for improvement of peripheral microcirculation in affected tissues, with application in age-related small-vessel pathology and microvascular insufficiency.
Peripheral & Cerebral Vascular Conditions
Emerging Evidence
Peripheral Vascular Disease
Conceptual application to atherosclerosis of lower-limb vessels, obliterating endarteritis, intermittent claudication, varicose veins, hemorrhoids, and thrombophlebitis — extrapolated from vascular wall mechanism and lipid-regulation data rather than direct RCTs.
Cerebral Circulation
Product descriptions list cerebral atherosclerosis and cerebral circulation disorders as application areas based on the tissue-specific vascular wall mechanism. Direct evidence in cerebrovascular conditions is limited.
Hypertension & Coronary Health
Arterial hypertension, coronary heart disease, and angiopathy of various genesis are listed as conceptual use areas. Evidence is extrapolated from the vascular epigenetic model; not confirmed by large independent trials.
Cardiovascular Aging & Longevity
Emerging Evidence
Anti-Aging Vascular Protocol
Within the Khavinson longevity framework, Ventfort is a first-class vascular bioregulator used in multi-organ aging protocols — often combined with Cardiogen (heart) and other organ-specific peptides to address systemic vascular aging and maintain vascular tissue gene expression patterns.
Angiogenesis & Endothelial Repair
Vascular peptide data suggest Ventfort promotes angiogenesis and endothelial repair, improving tissue perfusion and systemic resilience. Most data are cell/animal-level; human endothelial repair evidence is preliminary.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Product label explicitly lists peptide complex A-3 (aorta/blood-vessel peptides) at 10 mg per capsule. Capsule form should clearly identify aortic tissue origin.
Verified Marker
Lingual Concentration Specified
Lingual (sublingual) products explicitly state 10 mg A-3 per 1 mL (~5–6 drops). Unlabeled concentrations or missing per-drop dosing information are a yellow flag.
Verified Marker
Khavinson Institute–Associated Manufacturing
Manufactured under technology associated with the St. Petersburg Institute of Bioregulation and Gerontology, or licensed from the Khavinson technology base. The described verification process includes looking for Cytomax A-3 designation or Institute acknowledgment on packaging.
Quality Concern
No A-3 Identification or Third-Party Verification
Products that do not explicitly identify peptide complex A-3 or do not provide third-party laboratory verification of vascular peptide content should be avoided. The peptide complex designation is the primary quality marker.
Quality Concern
Unclear Origin or Inadequate Content Labeling
Inadequate labeling of peptide content per capsule or per drop, or unclear origin of the vascular peptide source, indicates a product that cannot be verified against the Khavinson clinical data.
Research Citations
Ventfort / A-3 vascular peptide bioregulator research originates primarily from the St. Petersburg Institute of Bioregulation and Gerontology. PubMed indexes approximately 30 studies on vascular Cytomax bioregulators over several decades. Key source types include:
Khavinson VKh et al. — Experimental studies on tissue-specific peptide complexes (organ-derived bioregulators) demonstrating selective action on isolated tissue cell types, improved trophism, and normalized functional/morphological changes.
IAS (International Aging Systems) clinical summary — Double-blind controlled study in patients with arterial atherosclerosis and senile purpura; documented improvements in vascular wall condition, microcirculation, and blood lipid profiles; reported good tolerability with no adverse effects.
Khavinson VKh — Peptides and Aging (monograph); Khavinson VKh, Anisimov VN — Geroprotective effects of epithalamine and other peptide bioregulators (Gerontology reviews).
SeekPeptides / modern longevity review literature — Commentary on epigenetic / connexin-normalization mechanisms and Cytomax stack design; not primary clinical data.
Khavinson development attribution. Stored encyclopedia origin text. Ventfort is a vascular-specific peptide bioregulator containing a complex of low-molecular-weight peptides (≤10,000 Da) isolated from the aortic tissue of young calves (≤12 months). Developed within the Khavinson Cytomax system at the St. Petersburg Institute of Bioregulation and Gerontology, it is studied for its ability to normalize metabolism and structure in blood-vessel wall cells, improve microcirculation, regulate blood lipids, and support arterial and venous health — with reported benefits in atherosclerosis, microcirculation disorders, senile purpura, and age-related vascular fragility. It is marketed as a biologically active food additive (dietary supplement) rather than a conventional pharmaceutical.
Note: Large-scale independent RCTs validating Ventfort are not yet available. The evidence base is preliminary and the above citations reflect the full scope of available data.
Research Focus
Vascular health, Endothelial function, Anti-aging, Blood vessel restoration, Cardiovascular health